Your session is about to expire
← Back to Search
Device
Evaluation of Low-cost Techniques for Detecting Sickle Cell Disease and β-thalassemia in Nepal and Canada
N/A
Waitlist Available
Led By Boris Stoeber
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights
No Placebo-Only Group
Summary
This trial evaluates low-cost screening techniques to detect sickle cell disease, sickle cell trait, and β-thalassaemia in remote/rural settings, to reduce mortality rate and improve quality of life.
Eligible Conditions
- Sickle Cell Trait
- Sickle Cell Anemia
- Sickle Cell-Beta Thalassemia
- Beta Thalassemia
- Sickle Cell Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Sensitivity, Specificity, Positive Predictive Value and Negative Predictive Value
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: 1) HbSS; 2) HbAS; 3) HbS/β-thalassemia; 4)Hbβ/β-thalassemia; 5) HbA/β- thalassemia; 6) HbAAExperimental Treatment6 Interventions
Around 20 participants each (in Nepal):
* with the homozygous form of sickle cell disease (HbSS)
* with the heterozygous form of sickle cell disease (HbAS)
* with the compound heterozygous form of sickle cell disease (HbS/β-thalassemia)
* with the carrier form of β-thalassemia (HbA/β-thalassemia)
* with the carrier form of β-thalassemia (HbA/β-thalassemia)
* without any known hemoglobin disorders, such as sickle cell disease, sickle cell trait, β-thalassemia, etc.
Around 30 participants each (in Canada):
* with the homozygous form of sickle cell disease (HbSS)
* with the heterozygous form of sickle cell disease (HbAS)
* without any known hemoglobin disorders, such as sickle cell disease, sickle cell trait, β-thalassemia, etc.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sickle SCAN
2022
N/A
~150
High performance liquid chromatography
2022
N/A
~150
Automated sickling test
2022
N/A
~150
Gazelle Hb Variant Test
2022
N/A
~150
HbS solubility test
2022
N/A
~150
HemoTypeSC
2022
N/A
~150
Find a Location
Who is running the clinical trial?
University of British ColumbiaLead Sponsor
1,481 Previous Clinical Trials
2,494,771 Total Patients Enrolled
Boris StoeberPrincipal InvestigatorUniversity of British Columbia